Founder’s Vision
ANKTIVA
BCG
Our Science
Careers
Contact
Patients & Caregivers
ANKTIVA®
Clinical Trials
Patients
Therapeutic Areas
Bladder Cancer
Glioblastoma
HIV
Human Papillomavirus
Lymphopenia
Lynch Syndrome
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Healthcare Providers
ANKTIVA®
Clinical Trials
Trial Investigators
Expanded Access
Researchers
Platforms & Modalities
Trial Investigators
Cell Licensing
Publications
Our Company
About
Pipeline
Contact
Compliance & Transparency
News and Events
Investors
Select Page
Acceptance Requirements
Adult patients diagnosed with CD19 and CD20-positive B-cell non-Hodgkin lymphoma
Have completed two lines of chemotherapy
Search for:
Recent Posts
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
LUGPA Regional Meeting
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
Jefferies Global Healthcare Conference 2025
